Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors

被引：1
|
作者：
Zhang, J. [1 ]
Liu, R. [1 ]
Gao, S. [1 ]
Li, X. [2 ]
Chen, J. [3 ]
Yao, X. [4 ]
Fang, Y. [5 ]
Li, R. [6 ]
Zhang, M. [7 ]
Qiu, F. [8 ]
Li, Y. [9 ]
Liu, T. [10 ]
Huang, H. [11 ]
Zhang, X. [12 ]
Guo, H. [13 ]
Hu, B. [14 ]
Liu, J-Y. [15 ]
Yang, Q. [16 ]
Zhao, P. [17 ]
Wang, P. [18 ]
机构：
[1] Shanghai Canc Ctr, Phase I Clin Trial Ctr, Shanghai, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China
[3] Yantai Yuhunagding Hosp, Dept Med Oncol, Yantai, Peoples R China
[4] Tianjin Canc Hosp, Dept Urol Oncol, Tianjin, Peoples R China
[5] Affiliated Canc Hosp Chongqing Univ, Dept Urol, Chongqing, Peoples R China
[6] Chongqing Univ Canc Hosp, Gynecol Oncol Ctr, Chongqing, Peoples R China
[7] Second Hosp Anhui Med Univ, Dept Med Oncol, Hefei, Peoples R China
[8] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Med Oncol, East Gate 1, Hangzhou, Peoples R China
[9] Shenyang Tenth Peoples Hosp, Dept Oncol, Shenyang, Peoples R China
[10] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[11] Wenzhou Med Univ, Affiliated Hosp 1, Dept Urinary Surg, Nanbaixiang Site, Wenzhou, Peoples R China
[12] Wuhan Union Hosp, Dept Urol, Wuhan, Peoples R China
[13] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Urol, Nanjing, Peoples R China
[14] Liaoning Canc Hosp & Inst, Dept Urol, Shenyang, Peoples R China
[15] Sichuan Univ, West China Hosp, West China Sch Med, Dept Biotherapy, Chengdu, Peoples R China
[16] Sun Yat Sen Univ, Affiliated Hosp 2, Phase I Clin Trial Ctr, Guangzhou, Peoples R China
[17] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China
[18] Mabwell Shanghai Biosci Co Ltd, Clin Med Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1845
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
659MO
引用
收藏
页码：S464 / S464
页数：1
相关论文
共 50 条
  • [41] Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
    Rottey, Sylvie
    Clarke, Jeffrey
    Aung, Kyaw
    Machiels, Jean-Pascal
    Markman, Ben
    Heinhuis, Kimberley M.
    Millward, Michael
    Lolkema, Martijn
    Patel, Sandip Pravin
    de Souza, Paul
    Duca, Matteo
    Curigliano, Giuseppe
    Santoro, Armando
    Koyama, Takafumi
    Brown, Michelle
    Vezina, Heather
    He, Chunsheng
    Chu, Quincy Siu-Chung
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 95 - 105
  • [42] A phase 1 study of BAT8007, an anti-nectin-4 monoclonal antibody-exatecan conjugate, in patients with advanced solid tumors.
    Jiang, Lijuan
    Song, Zhengbo
    Gong, Yi
    Jin, Jianan
    Ding, Yao
    Tang, Long
    Deng, Xia
    Li, Xiangdong
    Li, Su
    Cheng, Xiangdong
    Zhou, Fangjian
    Zhou, Xiaoyan
    Fu, Ziyi
    Yu, Jin-Chen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] First-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer
    Sharma, Manish
    Strickler, John H.
    Sommerhalder, David
    Kuboki, Yasutoshi
    Perets, Ruth
    Cohen, Jonathan
    Raimbourg, Judith
    Nakajima, Takako Eguchi
    Yamamoto, Noboru
    Cruz-Correa, Marcia
    O'Neil, Bert
    Ghiringhelli, Francois
    Raghav, Kanwal Pratap Singh
    Li, Rui
    Thiele, Gladys Morrison
    Aristide, Martha Raluca Neagu
    Freise, Kevin Jay
    de Almeida, Carla Biesdorf
    Vasilopoulos, Athanasios
    Powderly, John D., II
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
    Marathe, O.
    Cheng, Y.
    Spira, A. I.
    Hamilton, E. P.
    Rubinstein, M. M.
    Dong, X.
    Li, L.
    Lv, D.
    Shi, J.
    Gabrail, N.
    Amin, H.
    Wu, C.
    Zhu, Z.
    Qiu, Y.
    Gu, V.
    Qiu, X.
    Shi, R.
    Liu, L.
    Miao, P.
    Ueno, N. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S480 - S480
  • [45] A phase I study of SGN-STNV, a novel antibody-drug conjugate targeting sialyl-thomsen-nouveau antigen (STn), in adults with advanced solid tumors (SGNSTNV-001)
    Lakhani, N. J.
    Brana, I.
    Chiu, V. K.
    Dowlati, A.
    Lee, E. K.
    McGoldrick, S. M.
    Minchom, A.
    Tian, X.
    Patnaik, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S613 - S614
  • [46] Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors
    Qin, Shukui
    Cheng, Ying
    Wang, Qiming
    Cheng, Shuxia
    Chai, Xiaoli
    Wu, Lihua
    Yu, Yan
    Shi, Jianhua
    Li, Xiumin
    Fan, Lianlian
    Xia, Jin
    Huang, Yisheng
    Ji, Yinghua
    Zhuang, Zhixiang
    Yang, Lei
    Jiang, Ou
    Zheng, Qinhong
    Liao, Sihai
    Yi, Shanyong
    Ye, Huangyang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors
    Subbiah, V.
    Falchook, G.
    Davis, A. A.
    Wang, J. S.
    de Miguel, M.
    Santoro, A.
    Maur, M.
    Aljumaily, R.
    Boni, V.
    de Speville, B. Doger
    Sun, Y.
    Du, Y.
    Lakshmikanthan, S.
    Bedse, G.
    Ward, A.
    Zweidler-McKay, P.
    Gandhi, L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S72 - S73
  • [48] Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor α-Targeting Antibody-Drug Conjugate, in Patients With Solid Tumors
    Moore, Kathleen N.
    Borghaei, Hossein
    O'Malley, David M.
    Jeong, Woondong
    Seward, Shelly M.
    Bauer, Todd M.
    Perez, Raymond P.
    Matulonis, Ursula A.
    Running, Kelli L.
    Zhang, Xiaoyan
    Ponte, Jose F.
    Ruiz-Soto, Rodrigo
    Birrer, Michael J.
    CANCER, 2017, 123 (16) : 3080 - 3087
  • [49] A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors
    Rosen, Lee S.
    Wesolowski, Robert
    Baffa, Raffaele
    Liao, Kai-Hsin
    Hua, Steven Y.
    Gibson, Brenda L.
    Pirie-Shepherd, Steven
    Tolcher, Anthony W.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 120 - 130
  • [50] Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies
    Jonasch, Eric
    Call, Justin
    Kambhampati, Swetha
    Caimi, Paolo
    Curti, Brendan
    Diefenbach, Catherine
    Heath, Elisabeth
    Park, Steven
    Kornblum, Noah
    Li, Weidong
    Reimers, Melissa
    Spurgeon, Stephen
    Vaishampayan, Ulka
    Ye, Dingwei
    Zhang, Li
    Zhao, Weili
    Chen, Zhu
    Hunder, Naomi
    Ma, Sharon
    Song, Eric
    Garmezy, Benjamin
    ONCOLOGIST, 2023, 28
12345